Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: TARS.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Tarsus Pharmaceuticals (TARS) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$91

+16.1%

2031

5-Year

BUY

$145

+85.2%

Published batch insight

Ophthalmic Monopoly Faces Pipeline Absorption Before True Operating Cash Inflection

High consensus confirms XDEMVY commands an unassailable Demodex blepharitis monopoly with 93% gross margins, driving rapid revenue expansion toward commercial profitability. Sharp divergence centers on capital allocation: substantial upfront acquisition outlays, milestone commitments, and share dilution threaten to tax per-share compounding.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Warren Buffett (Value Purist), Ray Dalio (Strategist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Machiavelli (Insider), Elon Musk (Visionary), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Tarsus Pharmaceuticals at the forecast anchor (2026-09-18): $18,516 in five years versus $13,892 for S&P 500 benchmark.

Tarsus Pharmaceuticals · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Tarsus Pharmaceuticals compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 78.09 USD1-year price return: +16.07%5-year price return: +85.16%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	80.44	+3.01%	+3.01%	Third-quarter results confirm robust commercial demand near the upper guidance bound, but integration expenses from recent pipeline acquisitions and share dilution temper immediate valuation multiple expansion.
Q1 2027	83.29	+3.54%	+6.66%	Audited full-year results confirm approaching operational breakeven, though seasonal first-quarter insurance deductible resets and elevated research guidance keep equity appreciation at a measured pace.
Q2 2027	87.49	+5.05%	+12.04%	Operating leverage accelerates as first-quarter results demonstrate narrowing operating losses, while preliminary Phase 2 pipeline readouts spark renewed institutional confidence in platform durability.
Q3 2027	90.64	+3.59%	+16.07%	Prescription depth compounds across eye-care practices and international milestones contribute non-dilutive licensing revenue, buffering the equity against restrictive macroeconomic interest-rate headwinds.
Q4 2027	95.07	+4.89%	+21.74%	Delivery of inaugural sustained quarterly operating profitability confirms commercial scalability, prompting systematic multiple expansion as healthcare funds reclassify the company from speculative biotech to commercial compounder.
Q1 2028	97.62	+2.69%	+25.02%	Calendar-year financial disclosures confirm strong full-year operating cash generation, though routine annual payer deductible resets and ongoing Phase 3 trial expenses induce brief trading consolidation.
Q2 2028	102.08	+4.56%	+30.72%	European regulatory progress and expanding domestic prescriber penetration drive net product revenues past previous highs, confirming that fixed commercial overhead is decoupling from top-line gains.
Q3 2028	103.42	+1.32%	+32.44%	Gross-to-net discount friction from annual managed-care negotiations and summer clinic seasonality slightly moderate sequential growth, resulting in flat-to-modest equity consolidation.
Q4 2028	107.81	+4.24%	+38.06%	Commercial net product revenues cross an annualized one-billion-dollar run-rate, while steady 93% gross margins generate substantial free cash flow that self-funds expanding clinical commitments.
Q1 2029	109.78	+1.83%	+40.58%	Full-year results reflect solid operating cash flow exceeding two hundred million dollars, yet elevated trial spending on late-stage retinal programs temporarily caps rapid per-share earnings growth.
Q2 2029	115.10	+4.84%	+47.39%	Core ophthalmic cash generation provides a sturdy financial bridge as investor anticipation builds around pivotal late-stage clinical readouts, supporting disciplined institutional accumulation.
Q3 2029	119.38	+3.72%	+52.87%	Pivotal clinical trial data releases for pipeline assets drive event-driven valuation re-rating, validating the strategic transition toward a multi-franchise specialty pharmaceutical enterprise.
Q4 2029	123.02	+3.05%	+57.53%	Post-readout digestion and regulatory preparation costs moderately temper sentiment as investors evaluate commercialization budgets and milestone obligations against available operating cash balances.
Q1 2030	125.95	+2.38%	+61.28%	Reporting confirms durable cash compounding from the primary commercial asset, reassuring market participants that corporate operations remain self-funding without reliance on expensive debt markets.
Q2 2030	128.96	+2.39%	+65.14%	Supplemental indication filings and label expansion milestones broaden the addressable market, driving operating leverage as new revenues utilize established eye-care sales infrastructure.
Q3 2030	132.17	+2.49%	+69.25%	International commercial royalties from Europe and Asia begin flowing into operating income with negligible capital intensity, sustaining earnings compounding despite broader macroeconomic dispersion.
Q4 2030	136.11	+2.98%	+74.29%	Accumulating cash reserves prompt board authorization of capital return frameworks, reinforcing an earnings-based valuation floor as commercial maturity shifts focus to owner earnings yields.
Q1 2031	138.35	+1.65%	+77.17%	Routine early-year payer formulary true-ups and patent duration reviews slightly moderate multiple expansion, keeping equity valuation tightly tethered to delivered free cash flow.
Q2 2031	141.82	+2.51%	+81.62%	Predictable cash flows from mature ophthalmic market penetration and secondary pipeline contributions generate steady earnings per share growth, attracting value-oriented institutional capital.
Q3 2031	144.59	+1.95%	+85.16%	The company concludes the forecast horizon as an entrenched specialty pharmaceutical cash generator, trading in valuation equilibrium supported by strong cash yields and long-duration patent protection.

The base-case thesis rests on an entrenched commercial monopoly in Demodex blepharitis, where XDEMVY leverages routine optometric collarette screening across 25 million addressable hosts. Software-like 93% gross margins generate extreme operating leverage, turning trailing free cash flow positive and funding baseline operations. However, valuation sensitivity is governed by capital allocation: the recent acquisitions of Alkeus and iRenix commit over $300 million in upfront cash, expand pro forma shares, and create $537 million in contingent milestone claims alongside nearly doubled R&D guidance. The strongest counterargument highlights that XDEMVY is an acute six-week regimen rather than an ongoing daily therapy; replenishing the patient funnel demands persistent promotional expenditures that, combined with 45% gross-to-net payer deductions, could delay GAAP margin expansion beyond consensus expectations.

Key insights

Capital structure adjustments reveal that headline enterprise value gains will lag top-line growth due to private placement dilution and milestone claims.
Unit economics face continuous customer acquisition friction because finite six-week treatment courses require ongoing diagnostic education rather than providing automatic refills.
Pipeline optionality in Stargardt disease and Lyme prophylaxis offers transformative upside, but carries demanding clinical attrition hurdles and substantial carrying costs.

Deep Dive

Consensus views the asset as an uncontested single-product commercial success, celebrating XDEMVY's rapid ramp toward raised 2026 guidance of $685-705 million. Sell-side models extrapolate early prescriber momentum toward a $2 billion peak, treating unprofitability as a transient launch phase. However, the crowd anchors heavily on top-line script trajectories while largely dismissing the cash drain, milestone obligations, and share dilution stemming from recent clinical pipeline acquisitions.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates the asset's structural cash generation but misjudges its net investment profile, resulting in slight underpricing offset by capital drag. While consensus treats the company as an unprofitable launch story, trailing free cash flow has inflected positive at $61.5 million on 93% gross margins. The analytical edge lies in recognizing that while operating leverage is real, pro forma cash is thinner and milestone claims are heavier than headline numbers suggest, meaning per-share compounding will lag enterprise revenue growth.

Repricing catalyst

Sustained GAAP operating profitability across consecutive quarters in 2027 will shatter the cash-burn narrative and force institutional re-rating. Observable confirmation will appear as full-year 2026 reporting verifies XDEMVY revenues exceeding $700 million while SG&A growth decelerates relative to gross profit. This transition will compel generalist funds to re-rate the stock from a speculative clinical biotech to an earnings-driven commercial compounder, provided Phase 2 pipeline readouts confirm manageable ongoing R&D commitments.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of policy rates near 4.00% and elevated benchmark yields presents a mixed setup. Non-discretionary medical demand and self-funding operating cash flows provide structural insulation from broader consumer slowdowns and debt refinancing hurdles. However, elevated discount rates compress the valuation multiples assigned to long-duration clinical pipeline assets whose primary cash flows reside beyond 2029.

Published consensus context

Advisor disagreement

The critical analytical debate centers on whether Tarsus represents a self-funding commercial cash compounder or an aggressively dilutive clinical acquirer. Bulls argue that 93% gross margins and positive trailing free cash flow of $61.5 million make the commercial engine fully self-sustaining, ensuring rapid operating margin expansion past 30%. Contrarians demonstrate that committing $307.5 million in upfront acquisition cash, doubling R&D guidance, and assuming $537 million in contingent milestones significantly thins post-acquisition liquidity. This disagreement will be resolved by monitoring whether Q1 2027 net product revenues exceed $190 million without requiring additional equity raises.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Demodex standard-of-care category monopoly: XDEMVY commands an uncontested commercial monopoly as the sole FDA-approved therapeutic for Demodex blepharitis across 25 million addressable US hosts. Routine slit-lamp collarette screening is doubling high-frequency prescribers, expanding net sales toward guidance of $685-705 million. With patent protection extending to 2038, volume expansion flows directly into cash generation, cementing an impenetrable competitive moat. Expected impact: +42%.
Extreme operating leverage from gross margins: Manufacturing economics deliver elite 93% gross margins, ensuring incremental prescription revenue drops almost entirely into contribution profit. As nationwide optometric sales infrastructure stabilizes, top-line growth outpaces SG&A expansion. Trailing free cash flow has already inflected positive to $61.5 million, providing the foundation for sustained GAAP operating profitability and explosive earnings compounding. Expected impact: +32%.
International out-licensing and geographic expansion: Partner approvals, notably via Grand Pharma in Greater China, alongside planned European submissions unlock large patient populations with zero domestic promotional overhead. Foreign regulatory clearances activate milestone payments and high-margin tiered royalties. These capital-light foreign revenues flow straight to operating income, diversifying cash flows and extending the commercial life cycle. Expected impact: +18%.
Formulary access and demographic insulation: Securing preferred formulary access across commercial and Medicare Part D plans insulates prescription volume from consumer discretionary slowdowns. Demodex prevalence rises sharply with age, transforming ocular mite eradication into a non-cyclical demographic standard of care. High insured coverage reduces pharmacy counter abandonment, defending unit volumes through macroeconomic contractions. Expected impact: +14%.

Top frictions and headwinds

Portfolio acquisition cash and milestone drain: Acquiring Alkeus and iRenix committed $307.5 million in upfront cash and nearly doubled 2026 R&D guidance to $190-210 million to fund Phase 3 retinal trials. Additionally, $537 million in contingent milestone liabilities hangs over future cash flows. Siphoning commercial profits into late-stage clinical programs suppresses near-term net margins and delays capital distributions. Expected impact: -20%.
Gross-to-net payer rebate compression: Pharmacy benefit managers extract statutory rebates and concessions, maintaining gross-to-net deductions between 44% and 45%. As volume scales into broader managed-care and Medicare pools, payer scrutiny threatens to expand rebate leakage beyond 50%. This structural pricing drag depresses net realized price per bottle, requiring higher script volumes merely to preserve revenue projections. Expected impact: -15%.
Episodic therapy patient acquisition treadmill: Because XDEMVY is a finite six-week treatment rather than a chronic daily drop, treated patients rotate off therapy. Tarsus cannot rely on permanent refill annuities and must continually fund costly direct-to-consumer advertising to acquire naive patients. High recurring marketing requirements cap operating margin expansion and expose earnings to promotional fatigue. Expected impact: -14%.
Elevated discount rates compressing multiples: Federal Reserve policy rates near 4.00% and 10-year Treasury yields pressing 5.0% raise equity hurdle rates across biopharma. Higher discount factors compress the present value of long-dated pipeline cash flows, such as the 2029 NORTHSTAR trial. This macro drag imposes a valuation multiple discount, dampening share price gains relative to underlying operational execution. Expected impact: -12%.

Tail risks

Pivotal NORTHSTAR trial failure and write-down: The acquired asset gildeuretinol could fail to achieve statistical significance on retinal lesion slowing in the 2029 NORTHSTAR readout. Because inherited retinal degenerations carry severe clinical attrition, a trial failure would force immediate impairment of acquisition consideration, destroy market confidence in management's capital allocation, and collapse valuation back to a single-product baseline. Probability: +36%. Expected impact: -32%.
Early generic Paragraph IV patent breach: Generic filers could submit Abbreviated New Drug Applications with Paragraph IV certifications challenging lotilaner formulation patents following the expiration of statutory chemical exclusivity in 2028. An adverse court ruling invalidating delivery patents would permit premature bioequivalent entry, gutting XDEMVY's 93% gross margins and destroying long-term terminal value expectations. Probability: +22%. Expected impact: -42%.

Tail opportunities

NORTHSTAR Phase 3 Stargardt clinical triumph: A decisive efficacy readout from the pivotal Phase 3 NORTHSTAR trial of gildeuretinol in 2029 would establish the first approved oral therapy for Stargardt disease. Addressing 36,000 diagnosed US patients under Orphan Drug status would unlock an immediate $1.5 billion monopoly, transforming Tarsus into a diversified retinal powerhouse and triggering aggressive multiple expansion. Probability: +32%. Expected impact: +52%.
Strategic mega-pharma commercial buyout: A global pharmaceutical major seeking to replenish looming patent cliffs could launch an outright acquisition of Tarsus once sustained operating profitability is demonstrated. XDEMVY's 93% gross margins and 2038 patent exclusivity offer plug-and-play accretion, allowing an acquirer to eliminate redundant commercial overhead and justify a substantial cash takeover premium. Probability: +28%. Expected impact: +48%.

What to monitor

Thesis watchpoints

-- Confirmation: XDEMVY net product sales exceed $190 million quarterly by mid-2027 with gross margins holding firmly above 92%.

Key insights

Deterioration: Gross-to-net discount widening beyond 48% or sequential prescription growth dropping below 8% across two consecutive quarters.
Reassessment: An equity raise exceeding $150 million before the 2029 NORTHSTAR readout, indicating clinical milestones exceed operating cash.

Company Financial Analysis

Tarsus Pharmaceuticals Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Tarsus has achieved an impressive commercial breakout with its lead eye drop, XDEMVY. Net sales expanded rapidly to $451 million in 2025 and continued surging through mid-2026, reaching $174 million in the second quarter alone. While aggressive spending on advertising and clinical trials produced headline accounting net losses of $18.55 million, the underlying cash story is far more encouraging. Trailing twelve-month free cash flow inflected to positive $61.5 million, proving that day-to-day product sales generate substantial real cash. However, headline sales figures conceal an important detail: first-half 2026 revenue included a one-time $16.7 million international licensing milestone rather than recurring bottle sales. While recurring commercial demand is undeniably accelerating, future earnings growth will depend heavily on management's ability to control research expenses as guidance projects full-year sales approaching $700 million.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 451.4M	USD -66.4M	USD -22.3M
2024	USD 183M	USD -115.6M	USD -84.6M
2023	USD 17.4M	USD -135.9M	USD -123M
2022	USD 25.8M	USD -62.1M	USD -49.5M
2021	USD 57M	USD -13.8M	USD 3.2M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

The fundamental profit engine of Tarsus is defined by extraordinary gross margins of 93.2%. Because the chemical solution and eye dropper bottles cost pennies on the dollar to manufacture, almost every additional dollar of net sales represents pure gross profit. Operating margins improved dramatically from deep deficits worse than negative 65% in 2024 to negative 15.7% in 2025 as sales volume diluted overhead. Despite this elite unit profitability, GAAP operating margins remain negative because marketing and administrative expenses reached $150.7 million in the second quarter of 2026. Converting 93% gross margins into lasting bottom-line corporate profits requires prescription growth to naturally outrun commercial direct-to-consumer advertising and newly acquired research commitments.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -71M	-15.7%	-14.7%
2024	USD -120.6M	-65.9%	-63.2%
2023	USD -143.2M	-820.5%	-778.9%
2022	USD -62.7M	-242.9%	-240.5%
2021	USD -12.2M	-21.3%	-24.2%

Balance sheet and leverage

AI Review

On the surface, the balance sheet looks exceptionally liquid, closing the second quarter of 2026 with $449.7 million in cash and marketable securities alongside a low debt-to-equity ratio of 0.27. Management bolstered this liquidity with a $125 million private placement equity financing, giving the company strong short-term solvency and protecting it from high interest rates in credit markets. However, the balance sheet is thinner than headline figures suggest. The upfront cash for the Alkeus and iRenix acquisitions consumed over $300 million after the quarter closed. Furthermore, Tarsus took on roughly $537 million in contingent future milestone obligations tied to regulatory and clinical achievements. The business has adequate runway, but its financial cushion is closely tied to continued commercial execution.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 93.6M	USD 417.3M	USD 90M net cash	3.85x
2024	USD 72.5M	USD 291.4M	USD 22.4M net cash	4.42x
2023	USD 30.2M	USD 227.4M	USD 194.7M net cash	6.93x
2022	USD 20.2M	USD 217M	USD 51.5M net cash	14.61x
2021	USD 1.9M	USD 171.8M	USD 169.4M net cash	15.33x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Physical factory investment is practically non-existent, consuming just 2.18% of revenue in 2025. Tarsus relies on third-party contract manufacturing partners to blend and bottle lotilaner, avoiding the heavy capital expense and depreciation charges of owning industrial manufacturing facilities. This asset-light setup allows the company to direct virtually all available capital into marketing and clinical development. Yet true investment intensity exploded in mid-2026 through strategic corporate dealmaking. Management committed $307.5 million in upfront cash to acquire iRenix and Alkeus Pharmaceuticals, nearly doubling full-year research guidance to $190-210 million. While these purchases add exciting late-stage retinal therapies, they redirect commercial profits into long-duration clinical trials that will not produce commercial revenue until 2029 at the earliest.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 9.9M	USD 64.3M
2024	USD 1.6M	USD 53.4M
2023	USD 5.5M	USD 50.3M
2022	USD 506K	USD 42.6M
2021	USD 586K	USD 41.7M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	174	+18.3%	Not available	ORIGINAL
5Y	BUY	143	+102%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	73.4	81.16	83.56	14
+6M	March 18, 2027	70.47	84.57	89.4	14
+9M	June 18, 2027	74.76	89.06	95.66	14
+1Y	September 18, 2027	71.02	92.4	100.44	14
+15M	December 18, 2027	72.44	97.08	107.47	14
+18M	March 18, 2028	66.65	99.99	116.05	14
+21M	June 18, 2028	63.98	105.02	124.17	14
+2Y	September 18, 2028	64.62	107.15	130.38	14
+27M	December 18, 2028	61.39	112.1	138.2	14
+30M	March 18, 2029	57.71	114.9	149.26	14
+33M	June 18, 2029	59.44	121.06	158.21	14
+3Y	September 18, 2029	60.63	126.49	164.54	14
+39M	December 18, 2029	58.2	131.34	172.77	14
+42M	March 18, 2030	56.46	134.36	183.13	14
+45M	June 18, 2030	57.59	138.79	192.29	14
+4Y	September 18, 2030	56.43	142.88	198.06	14
+51M	December 18, 2030	58.13	147.28	205.98	14
+54M	March 18, 2031	56.97	150.26	216.28	14
+57M	June 18, 2031	58.1	154.37	222.77	14
+5Y	September 18, 2031	58.1	157.74	231.68	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

The Polymath

Gemini 3.8 Flash

Weight6.0/100

Demonstrates solid understanding of high contribution margins and operating leverage, but its multi-indication timeline assumes smooth clinical execution across adjacent pipelines.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight5.0/100

Articulates a clear consolidation thesis modeled on specialty pharma dynasties, but projects an excessively aggressive multi-billion equity expansion that minimizes clinical trial failure risks.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.0/100

Highlights Orange Book patent barriers through 2038 and managed care dynamics well, but underweights the immediate cash absorption of pivotal Phase 3 trials.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight4.0/100

Sound breakdown of gross profitability and pricing power, but exhibits redundant assumptions regarding commercial multiple expansion under restrictive monetary conditions.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight1.0/100

Detailed overview of operating leverage, but models a sudden outlier jump in late 2029 returns that is uncorroborated by broader clinical pipeline timelines.

Skip to references

Research Provenance

References & Context

This Tarsus Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 49 deduplicated sources retained for this batch.

01Drug Trials Snapshots: XDEMVY | FDAfda.gov
02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
03tars-20251231sec.gov
04tars-20260904sec.gov
05Tarsus Pharmaceuticals, Inc. - Form 10-Q - FY2026sec.gov
06Tarsus Pharmaceuticals, Inc. - Form 8-K - FY2026sec.gov
07Tarsus Pharmaceuticals, Inc. - Form 8-K - FY2026sec.gov
08Tarsus (TARS) Q2 2026 Earnings Call Transcript - AOLaol.com
09TARS Stock Quote Price and Forecast | CNNcnn.com
10Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...finance.yahoo.com
11Tarsus Pharmaceuticals Q2 Earnings Call Highlightsfinance.yahoo.com
12Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Careglobenewswire.com
13Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Careglobenewswire.com
14Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growthglobenewswire.com
15Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis | Tarsus Pharmaceuticalsir.tarsusrx.com

And 34 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.